Enlivex Therapeutics Ltd. (ENLV)

Market Cap	26.40M
Revenue (ttm)	n/a
Net Income (ttm)	-29.07M
Shares Out	18.59M
EPS (ttm)	-1.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	71,547
Open	1.470
Previous Close	1.450
Day's Range	1.365 - 1.480
52-Week Range	1.150 - 4.590
Beta	1.22
Analysts	Strong Buy
Price Target	7.00 (+392.96%)
Earnings Date	Mar 29, 2024

About ENLV

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. En...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 12, 1995
• Employees: 71
• Stock Exchange: NASDAQ
• Ticker Symbol: ENLV

Analyst Forecast

According to one analyst, the rating for ENLV stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target

$7.0

(392.96% upside)

Analyst Consensus: Strong Buy